Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 103-112

  Grau, S ^a,b   Thorsteinsdottir, J ^a   Von Baumgarten, L ^a   Winkler, F ^a   Tonn, J C ^a   Schichor, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Angiogenesis; Bevacizumab; Endothelial cells; Glioma; VEGF; VEGF C; VEGF D

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN C; VASCULOTROPIN D;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM CELL; GLIOBLASTOMA; GLIOMA CELL; GROWTH REGULATION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANNEXIN A5; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD31; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GLIOMA; HUMANS; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 80052713566     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0480-6     Document Type: Article

References (41)

1. J Folkman 2002 Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 15 18 12516034 1:CAS:528:DC%2BD3sXlvFSqtg%3D%3D
2. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 15637262 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar (Pubitemid 40093472)
3. RT Tong Y Boucher SV Kozin F Winkler DJ Hicklin RK Jain 2004 Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 3731 3736 15172975 10.1158/0008-5472.CAN-04-0074 1:CAS:528:DC%2BD2cXksVKgur8%3D (Pubitemid 38697278)
4. F Winkler SV Kozin RT Tong SS Chae MF Booth I Garkavtsev L Xu DJ Hicklin D Fukumura TE di LL Munn RK Jain 2004 Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 553 563 15607960 1:CAS:528:DC%2BD2MXktVantw%3D%3D (Pubitemid 40017699)
5. Y Crawford N Ferrara 2009 Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies Trends Pharmacol Sci 30 624 630 19836845 10.1016/j.tips.2009.09.004 1:CAS:528:DC%2BD1MXhsVGls7nP
6. RK Jain 2005 Antiangiogenic therapy for cancer: current and emerging concept Oncology (Williston Park) 19 7 16
7. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
8. J Jenab-Wolcott BJ Giantonio 2009 Bevacizumab: current indications and future development for management of solid tumors Expert Opin Biol Ther 9 507 517 19344286 10.1517/14712590902817817 1:CAS:528:DC%2BD1MXktFCjsr4%3D
9. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 12506171 10.1200/JCO.2003.10. 066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D
10. MR Machein KH Plate 2000 VEGF in brain tumors J Neurooncol 50 109 120 11245271 10.1023/A:1006416003964 1:STN:280:DC%2BD3Mzmsl2lsQ%3D%3D (Pubitemid 32166295)
11. KH Plate G Breier HA Weich W Risau 1992 Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 359 845 848 1279432 10.1038/359845a0 1:CAS:528:DyaK38XmsV2gsb8%3D
12. JI Greenberg DA Cheresh 2009 VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy Expert Opin Biol Ther 9 1347 1356 19761418 10.1517/14712590903208883 1:CAS:528:DC%2BD1MXht1CrsL3F
13. M Lohela M Bry T Tammela K Alitalo 2009 VEGFs and receptors involved in angiogenesis versus lymphangiogenesis Curr Opin Cell Biol 21 154 165 19230644 10.1016/j.ceb.2008.12.012 1:CAS:528:DC%2BD1MXksVClurk%3D
14. MR Machein KH Plate 2004 Role of VEGF in developmental angiogenesis and in tumor angiogenesis in the brain Cancer Treat Res 117 191 218 15015562 10.1007/978-1-4419-8871-3-13 1:CAS:528:DC%2BD2cXptFKiu70%3D
15. AK Olsson A Dimberg J Kreuger L Claesson-Welsh 2006 VEGF receptor signalling-in control of vascular function Nat Rev Mol Cell Biol 7 359 371 16633338 10.1038/nrm1911 1:CAS:528:DC%2BD28XjslSktrc%3D
16. TT Batchelor AG Sorensen TE Di WT Zhang DG Duda KS Cohen KR Kozak DP Cahill PJ Chen M Zhu M Ancukiewicz MM Mrugala S Plotkin J Drappatz DN Louis P Ivy DT Scadden T Benner JS Loeffler PY Wen RK Jain 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 17222792 10.1016/j.ccr.2006.11.021 1:CAS:528:DC%2BD2sXhtFClsLc%3D (Pubitemid 46075199)
17. N Ferrara 2005 VEGF as a therapeutic target in cancer Oncology 69 Suppl 3 11 16 16301831 10.1159/000088479 1:CAS:528:DC%2BD2MXht1aqsrnF (Pubitemid 41680948)
18. H Miletic SP Niclou M Johansson R Bjerkvig 2009 Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms Expert Opin Ther Targets 13 455 468 19335067 10.1517/14728220902806444 1:CAS:528: DC%2BD1MXjvVWnsr0%3D
19. HP Gerber N Ferrara 2005 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 671 680 15705858 1:CAS:528:DC%2BD2MXhtVWnsb0%3D (Pubitemid 40216420)
20. PL McCormack SJ Keam 2008 Bevacizumab: a review of its use in metastatic colorectal cancer Drugs 68 487 506 18318567 10.2165/00003495-200868040-00009 1:CAS:528:DC%2BD1cXmtFKlu74%3D (Pubitemid 351342019)
21. SJ Grau F Trillsch J Herms N Thon PJ Nelson JC Tonn R Goldbrunner 2007 Expression of VEGFR3 in glioma endothelium correlates with tumor grade J Neurooncol 82 141 150 17115285 10.1007/s11060-006-9272-4 1:CAS:528: DC%2BD2sXltFKhtro%3D (Pubitemid 46431856)
22. B Jenny JA Harrison D Baetens JC Tille K Burkhardt H Mottaz JZ Kiss PY Dietrich TN De GP Pizzolato MS Pepper 2006 Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas J Pathol 209 34 43 16523449 10.1002/path.1943 1:CAS:528:DC%2BD28XkvVSmtLw%3D
23. S Miebach S Grau V Hummel P Rieckmann JC Tonn RH Goldbrunner 2006 Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades J Neurooncol 76 39 48 16155723 10.1007/s11060-005-3674-6 1:CAS:528:DC%2BD28Xit12itL0%3D (Pubitemid 43115757)
24. F Ou-Yang KL Lan CT Chen JC Liu CL Weng CK Chou X Xie JY Hung Y Wei GN Hortobagyi MC Hung 2006 Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells Cancer Res 66 378 384 16397252 10.1158/0008-5472.CAN-05-1578 1:CAS:528:DC%2BD28XhsFWmsw%3D%3D (Pubitemid 43166045)
25. O Casanovas DJ Hicklin G Bergers D Hanahan 2005 Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 299 309 16226705 10.1016/j.ccr.2005.09.005 1:CAS:528:DC%2BD2MXhtFOrtLrF (Pubitemid 41443415)
26. RS Kerbel J Yu J Tran S Man A Viloria-Petit G Klement BL Coomber J Rak 2001 Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches Cancer Metastasis Rev 20 79 86 11831651 10.1023/A:1013172910858 1:CAS:528:DC%2BD38XhsVWlurs%3D (Pubitemid 34074682)
27. VS Brar RK Sharma RK Murthy KV Chalam 2009 Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells J Ocul Pharmacol Ther 25 507 511 20028259 10.1089/jop.2009.0028 1:CAS:528:DC%2BC3cXmtVehsQ%3D%3D
28. SY Lee DK Kim JH Cho JY Koh YH Yoon 2008 Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma Arch Ophthalmol 126 953 958 18625942 10.1001/archopht.126.7.953 1:CAS:528:DC%2BD1cXptFymu7o%3D (Pubitemid 352008378)
29. RK Sharma KV Chalam 2009 In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line Acta Ophthalmol 87 618 622 19563375 10.1111/j.1755-3768.2008.01410.x 1:CAS:528:DC%2BD1MXht1Gnt73P
30. Y Wang D Fei M Vanderlaan A Song 2004 Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 335 345 15886877 10.1007/s10456-004-8272-2 1:CAS:528:DC%2BD2MXktVajtL4%3D (Pubitemid 40767935)
31. BA Kallmann S Wagner V Hummel M Buttmann A Bayas JC Tonn P Rieckmann 2002 Characteristic gene expression profile of primary human cerebral endothelial cells FASEB J 16 589 591 11919163 1:CAS:528:DC%2BD38XivVOjt7c%3D
32. E Yoeruek MS Spitzer O Tatar S Aisenbrey KU Bartz-Schmidt P Szurman 2007 Safety profile of bevacizumab on cultured human corneal cells Cornea 26 977 982 17721300 10.1097/ICO.0b013e3180de1d0a (Pubitemid 47329805)
33. +-adenosine triphosphatase and zonula occludens 1 expression on cultured corneal endothelial cells Ophthalmic Res 44 43 49 20173357 10.1159/000286339 1:CAS:528:DC%2BC3cXntFSisbY%3D
34. DR Emlet KA Brown DL Kociban AA Pollice CA Smith BB Ong SE Shackney 2007 Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines Mol Cancer Ther 6 2664 2674 17938260 10.1158/1535-7163.MCT-07-0079 1:CAS:528:DC%2BD2sXhtFKltbbI (Pubitemid 350058147)
35. R Mentlein F Forstreuter HM Mehdorn J Held-Feindt 2004 Functional significance of vascular endothelial growth factor receptor expression on human glioma cells J Neurooncol 67 9 18 15072443 10.1023/B:NEON.0000021737.89357.cc (Pubitemid 38418244)
36. AK Lucio-Eterovic Y Piao JF de Groot 2009 Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Clin Cancer Res 15 4589 4599 19567589 10.1158/1078-0432.CCR-09-0575 1:CAS:528:DC%2BD1MXosV2lt7Y%3D
37. BA Moffat M Chen MS Kariaapper DA Hamstra DE Hall J Stojanovska TD Johnson M Blaivas M Kumar TL Chenevert A Rehemtulla BD Ross 2006 Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D Clin Cancer Res 12 1525 1532 16533777 10.1158/1078-0432.CCR-05-1408 1:CAS:528:DC%2BD28XitVGms7s%3D
38. SA Stacker C Caesar ME Baldwin GE Thornton RA Williams R Prevo DG Jackson S Nishikawa H Kubo MG Achen 2001 VEGF-D promotes the metastatic spread of tumor cells via the lymphatics Nat Med 7 186 191 11175849 10.1038/84635 1:CAS:528:DC%2BD3MXhtVylu74%3D (Pubitemid 32148485)
39. M Skobe T Hawighorst DG Jackson R Prevo L Janes P Velasco L Riccardi K Alitalo K Claffey M Detmar 2001 Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis Nat Med 7 192 198 11175850 10.1038/84643 1:CAS:528:DC%2BD3MXhtVylu7s%3D (Pubitemid 32148486)
40. H Kojima N Shijubo G Yamada S Ichimiya S Abe M Satoh N Sato 2005 Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma Cancer 104 1668 1677 16116610 10.1002/cncr.21366 1:CAS:528:DC%2BD2MXhtF2nt7rP (Pubitemid 41437430)
41. N Ferrara 2010 Pathways mediating VEGF-independent tumor angiogenesis Cytokine Growth Factor Rev 21 1 21 26 20005148 10.1016/j.cytogfr.2009.11.003 1:CAS:528:DC%2BC3cXivFKgsrg%3D